156 related articles for article (PubMed ID: 34195586)
1.
Zhang M; Ni Y; Zhou Q; He L; Meng H; Gao Y; Huang X; Meng H; Li P; Chen M; Wang D; Hu J; Huang Q; Li Y; Chauveau F; Li B; Chen S
EClinicalMedicine; 2021 Jul; 37():100982. PubMed ID: 34195586
[TBL] [Abstract][Full Text] [Related]
2. [
Carotenuto A; Giordano B; Dervenoulas G; Wilson H; Veronese M; Chappell Z; Polychronis S; Pagano G; Mackewn J; Turkheimer FE; Williams SCR; Hammers A; Silber E; Brex P; Politis M
Eur J Nucl Med Mol Imaging; 2020 Feb; 47(2):366-378. PubMed ID: 31637481
[TBL] [Abstract][Full Text] [Related]
3. Hybrid
Meng H; Zheng S; Yuan S; Zhou Q; Gao Y; Ni Y; He L; Yin D; Zhang M; Chen S
Transl Neurosci; 2022 Jan; 13(1):120-124. PubMed ID: 35795195
[TBL] [Abstract][Full Text] [Related]
4. Amyloid PET as a marker of normal-appearing white matter early damage in multiple sclerosis: correlation with CSF β-amyloid levels and brain volumes.
Pietroboni AM; Carandini T; Colombi A; Mercurio M; Ghezzi L; Giulietti G; Scarioni M; Arighi A; Fenoglio C; De Riz MA; Fumagalli GG; Basilico P; Serpente M; Bozzali M; Scarpini E; Galimberti D; Marotta G
Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):280-287. PubMed ID: 30343433
[TBL] [Abstract][Full Text] [Related]
5. Amyloid PET findings in multiple sclerosis are associated with cognitive decline at 18 months.
Pytel V; Matias-Guiu JA; Matías-Guiu J; Cortés-Martínez A; Montero P; Moreno-Ramos T; Arrazola J; Carreras JL; Cabrera-Martín MN
Mult Scler Relat Disord; 2020 Jan; 39():101926. PubMed ID: 31918239
[TBL] [Abstract][Full Text] [Related]
6. Insights into disseminated MS brain pathology with multimodal diffusion tensor and PET imaging.
Bezukladova S; Tuisku J; Matilainen M; Vuorimaa A; Nylund M; Smith S; Sucksdorff M; Mohammadian M; Saunavaara V; Laaksonen S; Rokka J; Rinne JO; Rissanen E; Airas L
Neurol Neuroimmunol Neuroinflamm; 2020 May; 7(3):. PubMed ID: 32123046
[TBL] [Abstract][Full Text] [Related]
7. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18).
Wong DF; Rosenberg PB; Zhou Y; Kumar A; Raymont V; Ravert HT; Dannals RF; Nandi A; Brasić JR; Ye W; Hilton J; Lyketsos C; Kung HF; Joshi AD; Skovronsky DM; Pontecorvo MJ
J Nucl Med; 2010 Jun; 51(6):913-20. PubMed ID: 20501908
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Standardized Uptake Value Ratio Calculations in Amyloid Positron Emission Tomography Brain Imaging.
Knešaurek K; Warnock G; Kostakoglu L; Burger C;
World J Nucl Med; 2018; 17(1):21-26. PubMed ID: 29398961
[TBL] [Abstract][Full Text] [Related]
9. Repurposing radiotracers for myelin imaging: a study comparing 18F-florbetaben, 18F-florbetapir, 18F-flutemetamol,11C-MeDAS, and 11C-PiB.
Auvity S; Tonietto M; Caillé F; Bodini B; Bottlaender M; Tournier N; Kuhnast B; Stankoff B
Eur J Nucl Med Mol Imaging; 2020 Feb; 47(2):490-501. PubMed ID: 31686177
[TBL] [Abstract][Full Text] [Related]
10.
Moscoso A; Silva-Rodríguez J; Aldrey JM; Cortés J; Pías-Peleteiro JM; Ruibal Á; Aguiar P;
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1242-1253. PubMed ID: 34581847
[TBL] [Abstract][Full Text] [Related]
11. Amyloid PET imaging in multiple sclerosis: an (18)F-florbetaben study.
Matías-Guiu JA; Cabrera-Martín MN; Matías-Guiu J; Oreja-Guevara C; Riola-Parada C; Moreno-Ramos T; Arrazola J; Carreras JL
BMC Neurol; 2015 Nov; 15():243. PubMed ID: 26607782
[TBL] [Abstract][Full Text] [Related]
12. 18F-florbetapir PET in patients with frontotemporal dementia and Alzheimer disease.
Kobylecki C; Langheinrich T; Hinz R; Vardy ER; Brown G; Martino ME; Haense C; Richardson AM; Gerhard A; Anton-Rodriguez JM; Snowden JS; Neary D; Pontecorvo MJ; Herholz K
J Nucl Med; 2015 Mar; 56(3):386-91. PubMed ID: 25655625
[TBL] [Abstract][Full Text] [Related]
13. Fingolimod treatment reverses signs of diffuse white matter damage in multiple sclerosis: A pilot study.
Saraste M; Bezukladova S; Sucksdorff M; Saunavaara V; Rissanen E; Matilainen M; Airas L
Mult Scler Relat Disord; 2021 Feb; 48():102690. PubMed ID: 33352357
[TBL] [Abstract][Full Text] [Related]
14. Comparison of
Zeydan B; Schwarz CG; Przybelski SA; Lesnick TG; Kremers WK; Senjem ML; Kantarci OH; Min PH; Kemp BJ; Jack CR; Kantarci K; Lowe VJ
J Nucl Med; 2022 Aug; 63(8):1239-1244. PubMed ID: 34916245
[TBL] [Abstract][Full Text] [Related]
15. Perilesional neurodegenerative injury in multiple sclerosis: Relation to focal lesions and impact on disability.
Clarke MA; Lakhani DA; Wen S; Gao S; Smith SA; Dortch R; Xu J; Bagnato F
Mult Scler Relat Disord; 2021 Apr; 49():102738. PubMed ID: 33609957
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous assessment of blood flow and myelin content in the brain white matter with dynamic [11 C]PiB PET: a test-retest study in healthy controls.
Yazdan-Panah A; Bodini B; Soulier T; Veronese M; Bottlaender M; Tonietto M; Stankoff B
EJNMMI Res; 2024 May; 14(1):50. PubMed ID: 38801594
[TBL] [Abstract][Full Text] [Related]
17. Reduced [
Moscoso A; Grothe MJ; Schöll M;
Eur J Nucl Med Mol Imaging; 2021 Jul; 48(7):2283-2294. PubMed ID: 33475761
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Visual and Quantitative Florbetapir F 18 Positron Emission Tomography Analysis in Predicting Mild Cognitive Impairment Outcomes.
Schreiber S; Landau SM; Fero A; Schreiber F; Jagust WJ;
JAMA Neurol; 2015 Oct; 72(10):1183-90. PubMed ID: 26280102
[TBL] [Abstract][Full Text] [Related]
19.
Datta G; Colasanti A; Kalk N; Owen D; Scott G; Rabiner EA; Gunn RN; Lingford-Hughes A; Malik O; Ciccarelli O; Nicholas R; Nei L; Battaglini M; De Stefano N; Matthews PM
J Nucl Med; 2017 Sep; 58(9):1477-1482. PubMed ID: 28302760
[TBL] [Abstract][Full Text] [Related]
20. Gray Matter Atrophy Is Primarily Related to Demyelination of Lesions in Multiple Sclerosis: A Diffusion Tensor Imaging MRI Study.
Tóth E; Szabó N; Csete G; Király A; Faragó P; Spisák T; Bencsik K; Vécsei L; Kincses ZT
Front Neuroanat; 2017; 11():23. PubMed ID: 28424595
[No Abstract] [Full Text] [Related]
[Next] [New Search]
